arrow
F

Frédéric Rolland

René Gauducheau
H指数:51
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin

在局部晚期头颈鳞状细胞癌且不适合顺铂治疗的患者中,关于放射治疗联合西妥昔单抗和xevinapant的双盲、安慰剂对照随机III期GORTEC 2022–01试验的终止。

2026-03-260
PRE
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12

高危局限性前列腺癌患者中无复发生存生存模型建模与竞争风险分析(GETUG-12治疗组)

2026-03-120
PRE
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study

转移性透明细胞肾细胞癌中的Nivolumab: 来自NIVOREN getug-afu 26 2期研究的综合生物标志物分析

2025-11-110
PRE
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

一项关于monalizumab和durvalumab在复发性/转移性头颈鳞状细胞癌患者中的II期研究:EORTC-HNCG-1559试验(UPSTREAM)中I2组的成果

2025-05-010
OAAI
Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial

Immunoscore-IC预测头颈鳞状细胞癌挽救性手术后辅助治疗中使用nivolumab的疗效:ADJORL1试验

2024-09-010
PRE
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
2024-09-010
PRE
Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

阿维鲁姆单抗-西妥昔单抗-放疗(RT)与标准治疗在局部晚期头颈鳞状细胞癌(LA-SCCHN)患者中的比较:随机III期GORTEC 2017-01 REACH试验的最终分析

2024-09-014
PRE
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
2024-08-010
PRE
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials

联合多西他赛与雄激素剥夺疗法在局部性和转移性激素敏感性前列腺癌中的获益由ERG表达预测:对两项GETUG III期试验的分析

2024-07-010
PRE
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
2024-07-010
OAAI
Adapted EXTREME regimen in the first-line treatment of fit older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, singlearm, phase 2 trial
2024-06-012
OA
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study
2024-04-011
PRE
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
2023-12-208
OA
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
2023-12-182
OAAI
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
2023-11-073
OAAI
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
2023-10-012
OA
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers
2023-09-016
PRE
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

Lenvatinib联合Pembrolizumab与舒尼替尼治疗晚期肾细胞癌的国际转移性肾细胞癌数据库联盟亚组按反应深度和疗效的生存率: 3期随机CLEAR研究分析

2023-08-0110
OAAI